AbbVie Inc. (ABBV)
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Abbvie confirms $2.1bn Capstan swoop
Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases and gaining access to a new type of RNA delivery system. The acquisition will give the pharma giant control of CPTX2309, a lipid nanoparticle-based therapy that delivers mRNA directly into the body to program the immune system.
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.
This Changes Everything: One Of The Most Important Shifts For Dividend Investors
Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its balance sheet and boost growth. That changes everything, including how we invest, where we invest, and why. I'm not overhauling my strategy. But I'm sharpening my focus on pricing power, hard assets, and income that's built for this new reality.
Best Dividend Aristocrats For July 2025
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising payouts in 2025 and an average growth rate of 4.86%. I identified 21 Aristocrats as both potentially undervalued and offering a projected long-term annualized return of at least 10%.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.
Jim Cramer's Safest Stock For Retirees
Jim Cramer has a mixed record when it comes to choosing stocks.
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
